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Boehringer Ingelheim and Pfizer have developed a unique continuous bioprocess consisting of a short duration 
perfusion upstream and fully integrated downstream.  The process is designed to generate at least 1 kg of 
material from a 100 L bioreactor in approximate 2 weeks.  The upstream strategy utilizes a non-steady state, 
short duration perfusion process to achieve volumetric productivities ranging from 0.5 to 4 g/L/day.  This creates 
a unique challenge for the downstream process as the titer and impurity load change over the duration of the 
culture.   
 
To accommodate upstream, a fully integrated downstream process was created using a combination of 
traditional batch unit operations and continuous bioprocessing.  The system design includes a pair of small 
proteins A columns operated consecutively, a continuous low pH inactivation chamber (cVI), an anion exchange 
chromatography column, a single pass tangential flow filter, a virus filter and batch UFDF.  The key to the 
system is three distinct operation modes including continuous, periodic and batch phases.  The resulting hybrid 
system provides flexible and robust downstream processing of the continuous perfusion bioreactor.  We have 
successfully used this new downstream process at the predicted manufacturing scale to generate clinical quality 
drug substance for multiple monoclonal antibodies. 
 
With the success of the new integrated system, our team is shifting its focus to implementation on a clinical 
program.  A key element of the ongoing work is to establish the control and robustness of novel elements of our 
process such as confirming that the critical pH has been achieved during cVI and demonstrating robust impurity 
removal for dynamic loading on an AEX polishing step. 
 
In this talk, we will explain our approach to integrated continuous downstream processing and our strategy for 
future implementation.  Data from at-scale demonstration runs will show the robustness of the process over a 
wide range of loading conditions.  This will include product quality data including HCP, DNA, charge variants 
and aggregate removal that is consistent with batch processes.  Process data will show the control and 
robustness of the approach.   
 
